SUPN Q4 2018 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$116M+31.1% YoY

Gross Profit

$112M96.4% margin

Operating Income

$40M34.4% margin

Net Income

$26M22.3% margin

EPS (Diluted)

$0.48

QoQ Revenue Growth

+12.6%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$33M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$978M

Total Liabilities

$525M

Stockholders' Equity

$453M

Cash & Equivalents

$192M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$116M	$88M	+31.1%
Gross Profit	$112M	$84M	+32.6%
Operating Income	$40M	$34M	+16.0%
Net Income	$26M	$14M	+89.6%